×

CellRapeutics™ CD19+ B Cells from Scleroderma Donor (XS-0426-XU7)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This cell population is isolated from Systemic Sclerosis donors, characterized by multi-organ fibrosis. These B cells are optimized for studies investigating the interplay between the immune system and fibroblasts. Research applications include exploring B cell-derived profibrotic cytokines and the signaling pathways that drive excessive extracellular matrix deposition and vasculopathy.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ CD19+ B Cells from Scleroderma Donor
  • Cat. No.
  • XS-0426-XU7
  • Donor Age
  • Middle-Aged
  • Donor Health
  • Clinically confirmed Systemic Sclerosis. Donors present with distinct fibrotic and vascular involvement profiles, often accompanied by disease-specific antinuclear antibodies.
  • Ethnicity
  • Diverse backgrounds available.
  • Anticoagulant
  • Acid Citrate Dextrose supplemented with Heparin, tailored to handle potential vasculopathy-related coagulation factor imbalances and protect B-cell metabolic flux.
  • Additional Donor Information
  • Each lot features CD19+ B cells from donors with Systemic Sclerosis. Profiles detail clinical subsets, specific autoantibody profiles, and organ involvement documentation.
  • Clinical Profile
  • Subtype classification, autoantibody status, and major organ involvement.

Additional Information

  • Medication History
  • Available upon request. Focuses on treatments for systemic involvement, including vasodilators, antifibrotic agents, and immunosuppressive therapies.
  • Formulation
  • Cryopreserved in specialized freezing medium
  • Cell Purity
  • >90%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Genetic Stability Testing
  • The donor cells maintain their native genetic profile, exhibiting no karyotypic abnormalities or chromosomal instabilities typically associated with prolonged ex vivo expansion.
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each product batch undergoes rigorous testing for purity, viability, and microbial contamination.
  • Storage
  • Upon arrival, immediately transfer the vial to the liquid nitrogen.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Upon thawing, it is recommended to rapidly thaw the cells in a 37°C water bath, followed by the slow addition of pre-warmed culture medium to minimize osmotic shock.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1E7 cells/vial, 2.5E7 cells/vial
  • Keywords
  • CellRapeutics™ CD19+ B Cells from Scleroderma Donor, CD19+ B Cells, Scleroderma

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ CD19+ B Cells from Scleroderma Donor (XS-0426-XU7). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.